Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/9290
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | ALONSO ABAD, Ariel | - |
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.contributor.author | RENARD, Didier | - |
dc.contributor.author | Darstein, Christelle | - |
dc.date.accessioned | 2009-03-02T10:13:45Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 19(2). p. 256-272 | - |
dc.identifier.issn | 1054-3406 | - |
dc.identifier.uri | http://hdl.handle.net/1942/9290 | - |
dc.description.abstract | In recent years the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates. Biomarkers for efficacy and safety could be a plausible strategy to improve this selection process. In the present work, we focus on the study and evaluation of different physiological variables as biomarkers for pharmacological activity. We proposed three different approaches using multivariate and univariate techniques. We note that even though one could argue that the multivariate procedure is more powerful than the other alternatives, the univariate methods also offer a great flexibility to answer interesting scientific questions. The three approaches were used to analyze a crossover study involving an opioid antagonist. | - |
dc.description.sponsorship | Ariel Alonso and Geert Molenberghs gratefully acknowledge financial support from the Interuniversity Attraction Pole Research Network P6/03 of the Belgian Government (Belgian Science Policy). All authors are grateful to Eli Lilly & Company for graciously providing the data. | - |
dc.format.extent | 285544 bytes | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.subject.other | Biomarkers; Crossover; Optimization; Surrogate marker | - |
dc.subject.other | biomarkers; crossover; optimization; surrogate marker | - |
dc.title | Evaluation of Biomarkers for Pharmacological Activity | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 272 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 256 | - |
dc.identifier.volume | 19 | - |
local.format.pages | 17 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Alonso, Ariel; Molenberghs, Geert] Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium. [Renard, Didier] Novartis Pharma AG, Exploratory Dev, Clin Informat Sci, Basel, Switzerland. [Darstein, Christelle] Lilly Corp Ctr, Lilly Serv SA, Program Phase Stat, Indianapolis, IN USA. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1080/10543400802622386 | - |
dc.identifier.isi | 000263291400003 | - |
item.fulltext | With Fulltext | - |
item.contributor | ALONSO ABAD, Ariel | - |
item.contributor | MOLENBERGHS, Geert | - |
item.contributor | RENARD, Didier | - |
item.contributor | Darstein, Christelle | - |
item.fullcitation | ALONSO ABAD, Ariel; MOLENBERGHS, Geert; RENARD, Didier & Darstein, Christelle (2009) Evaluation of Biomarkers for Pharmacological Activity. In: JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 19(2). p. 256-272. | - |
item.accessRights | Open Access | - |
item.validation | ecoom 2010 | - |
crisitem.journal.issn | 1054-3406 | - |
crisitem.journal.eissn | 1520-5711 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
alonso2009.pdf Restricted Access | Published version | 513.14 kB | Adobe PDF | View/Open Request a copy |
GeertMolenberghs3.pdf | Peer-reviewed author version | 288.92 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.